Status:
COMPLETED
Euphrasia Eye Drops in Preterm Infants With First Signs of Congestion of Nasolacrimal Duct
Lead Sponsor:
University of Bern
Conditions:
Congenita Nasolacrimal Duct Obstruction
Preterm Neonates
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
Congenital nasolacrimal duct obstruction (CNLDO) occurs in approximately 10 to 20% of all term newborns, and is the most common cause of persistent tearing and ocular discharge in children. CNLDO caus...
Eligibility Criteria
Inclusion
- Preterm neonates (with a gestational age of 24 to 37 weeks)
- Presenting with first signs of a congestion of the nasolacrimal duct, i.e. white, yellow, or green ocular discharge with or without tearing and reddened eye.
- Written informed consent by the parents or legal guardians
Exclusion
- Congenital abnormalities of the eye
- Ophtalmia neonatorum
- Severe asphyxia
- Sepsis
- Intracranial bleeding (intraventricular hemorrhage ≥ grade III)
Key Trial Info
Start Date :
May 22 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 16 2016
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT04122300
Start Date
May 22 2011
End Date
December 16 2016
Last Update
October 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neonatology, Children University Hospital of Bern
Bern, Switzerland, 3010